[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news
New Standard of Care for Early dMMR/MSI-H Colorectal Cancer? New Standard of Care for Early dMMR/MSI-H Colorectal Cancer?
Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 17, 2023 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Biomarkers Measure Neoadjuvant Response in Pancreatic Cancer Biomarkers Measure Neoadjuvant Response in Pancreatic Cancer
Could certain biomarkers be an indicator of response to neoadjuvant treatment in pancreatic cancer patients?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
PD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC
FRIDAY, Jan. 13, 2023 -- For localized mismatch repair-deficient (dMMR) colorectal cancer (CRC), neoadjuvant programmed death-1 (PD-1) inhibitor treatment is effective, according to a study published online Jan. 11 in the Journal of the National... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2023 Category: Pharmaceuticals Source Type: news
High Response Rate With Neoadjuvant Anti-PD-1 in Localized dMMR Colorectal Cancer
(MedPage Today) -- Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients with localized and locally advanced colorectal cancer (CRC) with mismatch repair deficiency (dMMR)/high microsatellite instability ... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 13, 2023 Category: Gastroenterology Source Type: news
Recurrence Score Indicates When to Use Endocrine Therapy Recurrence Score Indicates When to Use Endocrine Therapy
Scores on a breast recurrence assay may signal which patients can get neoadjuvant endocrine therapy vs chemotherapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Immunochemotherapy Promising in Oral SCC Neoadjuvant Immunochemotherapy Promising in Oral SCC
A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Optimal Surgery Timing After Chemo in Esophageal Cancer? Optimal Surgery Timing After Chemo in Esophageal Cancer?
New data show that survival outcomes were best when surgery came 6 –8 weeks after neoadjuvant chemotherapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mesothelioma Surgery With Immunotherapy Proves Effective in Study
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine.
The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective.
This randomized clinical trial compared the use of durvalumab alone – already shown to be effective in other cancers – to both the two-drug combination and to using no immunotherapy before mesothelioma surgery.
Clinica...
Source: Asbestos and Mesothelioma News - December 19, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news
Marker May Explain Poor Outcomes in Black Breast Cancer Patients Marker May Explain Poor Outcomes in Black Breast Cancer Patients
A study of tumor microenvironments suggests that breast tumors in Black women may have a stronger prometastatic response to neoadjuvant chemotherapy than tumors in White women.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
In Early-Stage NSCLC, Give Nivolumab Before or After Surgery? In Early-Stage NSCLC, Give Nivolumab Before or After Surgery?
Dr Mark Kris discusses the choice between neoadjuvant and adjuvant nivolumab for patients with early-stage lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Where Are Checkpoint Inhibitors Standard of Care for NSCLC? Where Are Checkpoint Inhibitors Standard of Care for NSCLC?
Dr Mark Kris discusses the use of checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with non-small cell lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Advances in Non-Small Cell Lung Cancer From SITC 2022 Advances in Non-Small Cell Lung Cancer From SITC 2022
The role of gene mutations in outcomes and treatment resistance, a novel LAG-3 inhibitor, and the case for neoadjuvant therapy are among the NSCLC highlights from SITC 2022 reported by Dr Jack West.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Neoadjuvant Therapy Improves Survival in Metastatic Colon Cancer Neoadjuvant Therapy Improves Survival in Metastatic Colon Cancer
Among patients with metastatic colon cancer with liver or lung lesions who received neoadjuvant therapy, survival was longer in comparison with patients who received adjuvant therapy, but only in nonacademic settings.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 18, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
